Pregnant women, long excluded from drug trials, are back in the spotlight Press Coverage Pregnant women, long excluded from drug trials, are back in the spotlight Certara’s Karen Yeo discusses FDA’s draft guidance to include pregnant and breastfeeding women in clinical…CertaraOctober 17, 2025
PKUK 2025 Pre-Conference Workshop: Modeling & Simulation Updates – QSP and PK/PD Software Live Events PKUK 2025 Pre-Conference Workshop: Modeling & Simulation Updates – QSP and PK/PD Software -CertaraOctober 14, 2025
Essentials of Model-informed Drug Development in Oncology Blog Essentials of Model-informed Drug Development in Oncology Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs.…CertaraOctober 6, 2025
Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science Announcement Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…CertaraSeptember 22, 2025
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool Announcement Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…CertaraSeptember 17, 2025
Modeling Approaches for Determination of Pharmacokinetics/Pharmacodynamics Press Coverage Modeling Approaches for Determination of Pharmacokinetics/Pharmacodynamics Explore insights from Certara experts on how PK/PD modeling streamlines biologic drug development.CertaraAugust 5, 2025
Breaking New Ground: EMA Qualification of the Simcyp® Simulator Ushers in a New Era for PBPK Modeling Blog Breaking New Ground: EMA Qualification of the Simcyp® Simulator Ushers in a New Era for PBPK Modeling The Simcyp Simulator receives EMA qualification—the first and only PBPK platform formally qualified for any…CertaraAugust 5, 2025
Mechanistic Models at the Regulatory Frontier: Insights from EMA’s Qualification of the Simcyp® Simulator On-Demand Webinar Mechanistic Models at the Regulatory Frontier: Insights from EMA’s Qualification of the Simcyp® Simulator The European Medicines Agency (EMA) formally qualified Certara’s Simcyp® Simulator, marking the first and only…CertaraAugust 4, 2025
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling Press Release Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling Certara announces that EMA has formally qualified the Simcyp® Simulator for use in regulatory submissions…CertaraAugust 4, 2025